Expert Review of Anti-Infective Therapy This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Part 2: understanding the role of Malassezia spp. In skin disorders: pathogenesis of Malassezia associated skin infections
Expert Rev Anti Infect Ther. 2023 Oct 26. doi: 10.1080/14787210.2023.2274500. Online ahead of print.ABSTRACTINTRODUCTION: Malassezia is a major component of the skin microbiome, a lipophilic symbiotic organism of the mammalian skin, which can switch to opportunistic pathogens triggering multiple dermatological disorders in humans and animals. This phenomenon is favored by endogenous and exogenous host predisposing factors, which may switch Malassezia from a commensal to a pathogenic phenotype.AREA COVERED: This review summarizes and discusses the most recent literature on the pathogenesis of Malassezia yeasts, which ultima...
Source: Expert Review of Anti-Infective Therapy - October 26, 2023 Category: Infectious Diseases Authors: Iniobong Chukwuebuka Ikenna Ugochukwu Wafa Rhimi Wissal Chebil Antonio Rizzo Maria Tempesta Gustavo Giusiano Raul Fernando Mej ía Tábora Domenico Otranto Claudia Cafarchia Source Type: research

Part 1: understanding the role of Malassezia spp. In skin disorders: Malassezia yeasts as commensal or pathogenic organisms of human and animal skin
Expert Rev Anti Infect Ther. 2023 Oct 26. doi: 10.1080/14787210.2023.2276367. Online ahead of print.ABSTRACTMALASSEZIA: spp. are a group of lipid-dependent basidiomycetes yeasts acting as commensal organisms of the human and animal skin. However, under some not well-defined circumstances, these yeasts may switch to opportunistic pathogens triggering a number of skin disorders with different clinical presentations. The genus comprises of 18 lipid-dependent species with a variable distribution in the hosts and pathologies thus suggesting a host- and microbe-specific interactions.AREA COVERED: This review highlighted and disc...
Source: Expert Review of Anti-Infective Therapy - October 26, 2023 Category: Infectious Diseases Authors: Iniobong Chukwuebuka Ikenna Ugochukwu Wafa Rhimi Wissal Chebil Antonio Rizzo Maria Tempesta Gustavo Giusiano Raul Fernando Mej ía Tábora Domenico Otranto Claudia Cafarchia Source Type: research

Contemporary pharmacologic treatments of MRSA for hospitalized adults: rationale for vancomycin versus non-vancomycin therapies as first line agents
Expert Rev Anti Infect Ther. 2023 Oct 24. doi: 10.1080/14787210.2023.2275663. Online ahead of print.ABSTRACTINTRODUCTION: Methicillin-resistant Staphylococcus aureus (MRSA) remains an important pathogen in the hospital setting and causes significant morbidity and mortality each year. Since the initial discovery over 60 years ago, vancomycin has remained a first-line treatment for many different types of MRSA infections. However, significant concerns related to target attainment and nephrotoxicity have spurred efforts to develop more effective agents in the last two decades.AREAS COVERED: Newer anti-MRSA antibiotics that ha...
Source: Expert Review of Anti-Infective Therapy - October 25, 2023 Category: Infectious Diseases Authors: Jack Chang Ardita Tasellari Jamie L Wagner Marc H Scheetz Source Type: research

Nontuberculous mycobacterial pulmonary disease and the potential role of SPR720
Expert Rev Anti Infect Ther. 2023 Oct 20:1-11. doi: 10.1080/14787210.2023.2270158. Online ahead of print.ABSTRACTINTRODUCTION: Nontuberculous mycobacteria infect patients who have structural lung disease or those who are immunocompromised. Nontuberculous mycobacterial pulmonary disease (NTM-PD) is increasing in prevalence. Treatment guidelines for Mycobacterium avium complex (MAC) pulmonary disease involve a three-drug regimen with azithromycin, ethambutol, and rifampin, and those of Mycobacterium abscessus complex (MAB) pulmonary disease involve a combination of three or more antimicrobials including macrolides, amikacin,...
Source: Expert Review of Anti-Infective Therapy - October 20, 2023 Category: Infectious Diseases Authors: Kevin L Winthrop Patrick Flume Kamal A Hamed Source Type: research

Effect of tixagevimab/cilgavimab for pre-exposure prophylaxis during the China Omicron outbreak
CONCLUSION: Tixagevimab/cilgavimab may have protected high-risk populations against infection with the Omicron variant, hospitalization and severe disease during the China COVID-19 pandemic.PMID:37855094 | DOI:10.1080/14787210.2023.2272866 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - October 19, 2023 Category: Infectious Diseases Authors: Jianhua You Jiaxin Tian Haidi Wu Wenyan Kang Jianru Wen Hongwei Xu Wenbo Shi Zhi Wang Hanyu Wei Yanjun Du Xiang Li Guangyuan Mu Min Zhou Zhidong Gu Jieming Qu Source Type: research

Clinical trials aimed at HIV cure or remission: new pathways and lessons learned
Expert Rev Anti Infect Ther. 2023 Oct 19. doi: 10.1080/14787210.2023.2273919. Online ahead of print.ABSTRACTINTRODUCTION: The main barrier to finding a cure against HIV is the latent HIV reservoir, which persists in people living with HIV (PLWH) despite antiretroviral treatment (ART). Here, we discuss recent findings from interventional studies using mono- and combination therapies aimed to enhance immune-mediated killing of the virus with or without activating HIV from latency.AREAS COVERED: We discuss latency reversal agents (LRAs), broadly neutralizing antibodies, immunomodulatory therapies, studies aimed at inducing ap...
Source: Expert Review of Anti-Infective Therapy - October 19, 2023 Category: Infectious Diseases Authors: Maya Dyveke Schou Ole Schmeltz S øgaard Thomas Aagaard Rasmussen Source Type: research

Synergistic effects of eravacycline combined with fluconazole Against resistant Candida albicans in vitro and in vivo
CONCLUSIONS: These results indicate that the combination of ERV and FLC effectively inhibits resistant C. albicans both in vitro and in vivo and lay the foundation for a potential novel treatment option for candidiasis.PMID:37818633 | DOI:10.1080/14787210.2023.2270160 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - October 11, 2023 Category: Infectious Diseases Authors: Xiuyun Li Huijun Yang Ximeng Duan Min Cui Wenlan Xing Shicun Zheng Source Type: research